Andrea Grubb Barthwell, M.D., D.F.A.S.A.M., is a Director at the comprehensive wellness center for the treatment of alcoholism and substance use disorders, Two Dreams Outer Banks and is the Chief Medical Officer of The Manor, Madison, Wisconsin. She is the founder and Chief Executive Officer of the Washington, DC-based global health care and policy-consulting firm EMGlobal LLC.
Genie Bailey, is currently an Associate Clinical Professor of Psychiatry and Human Behavior at the Warren Alpert Medical School of Brown University and is a Board Certified psychiatrist with 30 plus years of clinical and supervisory experience. She is also Diplomate of the American Board of Addiction Medicine and a Fellow in American Society of Addiction Medicine. Over the last decade, she has focused on substance abuse treatment and research at an internationally known treatment center, Stanley Street Treatment and Resources, Inc. (SSTAR) which is located in Fall River, Massachusetts.
Sonnie Kim serves as Vice President of Medical & Scientific Affairs at Braeburn Pharmaceuticals. She has nearly 20 years of leadership experience driving medical affairs and scientific programs across a range of therapeutic areas, including pain management, addiction medicine and cardiovascular disease.
Shruti Kulkarni is the Policy Director for the Center for Lawful Access and Abuse Deterrence (CLAAD), a not-for-profit organization working to reduce prescription drug abuse. In this role, she develops policy strategies to improve health care for individuals whose health or treatment has been affected by the nation’s prescription drug abuse and heroin epidemic. She is also a health care policy advisor at DCBA Law & Policy, a Washington, DC-based law firm.
Sharon Walsh, Ph.D. Is a Professor of Behavioral Science, Psychiatry, Pharmacology and Pharmaceutical Sciences and Director of the Center on Drug and Alcohol Research at the University of Kentucky. She has been conducting clinical research in substance abuse for nearly 25 years- much of it focused on understanding the behavioral pharmacology of opioid dependence and developing/improving pharmacotherapies for treatment of opioid dependence, including methadone and buprenorphine. She has published 100+ papers and book chapters, lectures widely on the topic and serves as a consultant to the FDA and other federal and state agencies.